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Abstract To verify whether the sleep-inducing properties of
oleamide were related to its ability to perturb membrane
homeoviscosity, affecting 5-HT2A receptors, we compared the
effects of oleamide and oleic acid, the latter lacking both the
sleep-inducing effect and the action on 5-HT2A receptors. In
binding studies the two compounds did not directly interact with
rat brain cortex 5-HT2A receptors, nor did they increase the
affinity of a 5-HT2A agonist, either in vitro or ex vivo. They had
similar fluidizing effects, in vitro at high concentrations (v10
WM), and ex vivo after a dose of 100 mg/kg, and they reduced
locomotor activity with similar potency. There thus appears to be
no causal relationship between the fluidizing effects of oleamide
and its sleep-inducing properties.
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1. Introduction
Oleamide (cis-9,10-octadecenoamide) is a sleep-inducing
amidated lipid originally discovered in the cerebrospinal £uid
of sleep-deprived cats [1]. Among its biochemical e¡ects, ole-
amide was reported to inactivate gap junction channels [2] and
to modulate the activity of some receptors including serotonin
(5-HT) 5-HT2 [3] and 5-HT7 [4] receptors. Oleamide potenti-
ated the e¡ect of 5-HT on chloride currents of frog oocyte
expressing 5-HT2A receptors [3], and also on inositol-phos-
phate formation in rat P11 cells, which endogenously express
the 5-HT2A subtype [4]. It was suggested that these e¡ects
were due to an allosteric action of oleamide on 5-HT2A re-
ceptors since it did not a¡ect the chloride currents or inositol-
phosphate formation. Thus, evidence that 5-HT receptors
were involved in sleep regulation or in the e¡ects of sleep
deprivation [5^7] suggested that oleamide’s sleep-inducing ef-
fects may be linked to its actions on 5-HT neurotransmission
[3].
Chemically, oleamide is composed of a long alkane chain
with a centrally placed cis double bond and a primary amide
with strong hydrogen bonding potential. It was therefore sug-
gested that this molecule could potentially disrupt membrane
homeoviscosity more than its free fatty acid analogs [8]. It was
thus opined that oleamide might be a new neuromodulator
which, by perturbing membrane homeoviscosity, would selec-
tively a¡ect the conformation and activity of membrane pro-
teins sensitive to the lipid environment, such as 5-HT2A re-
ceptors or the gap junction membrane channels [8,9]. This
suggestion was reinforced by evidence that oleic acid, which
lacks the primary amide group, did not modify the sponta-
neous sleep-waking cycle [1] and had not e¡ect on either gap
junction channels [2] or 5-HT neurotransmission [3,4].
This study was aimed at clarifying how the membrane ho-
meoviscosity perturbation is involved in oleamide’s hypnotic
e¡ect, with particular regard to the brain 5-HT2A receptor-
mediated e¡ects.
2. Materials and methods
2.1. Animals
Male CRL:CD(SD)BR rats (Charles River, Italy), weighing about
250 g, were used. Procedures involving animals and their care were
conducted in conformity with the institutional guidelines that are in
compliance with national (D.L. n. 116, G.U., suppl. 40, Feb. 18, 1992)
and international laws and policies (EEC Council Directive 86/609, OJ
L 358, 1, Dec. 12, 1987; Guide for the Care and Use of Laboratory
Animals, U.S. National Research Council, 1996).
Rats were treated intraperitoneally with oleamide, oleic acid or
vehicle (ethanol:water, 1:1, 2 ml/kg). Behavioral studies were con-
ducted from 20 to 40 min after the injection, whereas for the ex
vivo studies rats were killed by decapitation 30 min after treatment.
Untreated rats were used for the in vitro binding studies.
After decapitation, the brain cortices were rapidly dissected out and
used to prepare the crude synaptosomal pellet (P2) [10]. The cortices
were homogenized in 20 volumes of 0.32 M sucrose, pH 7.4, and
centrifuged for 5 min at 1000Ug. The supernatant was centrifuged
again at 12 000Ug for 20 min to yield the P2 pellet.
2.2. Behavioral measurements
Behavioral studies were conducted from 20 to 40 min after i.p.
doses of 12.5, 25, 50 or 100 mg/kg of oleamide or oleic acid. Controls
received vehicle alone.
Locomotor activity was measured in Makrolon cages (20.5U28U21
cm), with two horizontal photocell beams along the long axis, 3 cm
above the £oor and 18 cm apart. Interruptions of the light beams were
recorded by a Paul Fray Ltd computer (Cambridge, U.K.) with Spider
software. The room containing the activity cages was closed and ven-
tilated; it had dim indirect lighting, with one 15 W incandescent bulb.
A loudspeaker about 1 m above the cages masked extraneous noise.
Rats were placed in the cage 20 min after the oleamide, oleic acid or
vehicle injection and their locomotor activity was measured for 20 min.
The loss of the righting re£ex was used to assess the compounds’
sleep-inducing properties, as described previously [11].
2.3. Membrane microviscosity
Membrane microviscosity was determined by the £uorescence po-
larization (FP) technique [12], using 1,6-diphenyl-1,3,5-hexatriene
(DPH, Molecular Probes) as a £uorescent probe. The P2 pellets
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were resuspended in about 300 volumes of 5 mM phosphate bu¡er,
pH 7.4, and preincubated with 2 WM DPH for 30 min at room tem-
perature. For in vitro studies, the direct e¡ect of oleamide and oleic
acid was investigated on control rat brain synaptosomal membrane
preparations. The FP value was recorded at 25‡C, before and 30 s
after the addition of 30 Wl of oleamide or oleic acid (30 nM^20 WM),
or vehicle into the cuvette. In ex vivo studies the FP value of brain
synaptosomal membrane preparations from rats injected i.p. 30 min
earlier with oleamide or oleic acid (12.5^100 mg/kg) or vehicle alone,
was measured.
The FP value is related to the emission (420 nm), detected through
an analyzer oriented parallel (FP1) and perpendicular (FP2) to the
polarization of the exciting light (365 nm), according to the equation
FP = (FP23FP1)/(FP1+FP2) [12]. Membrane microviscosity (R, poise)
is related to the FP value according to the equation R= 2FP/
(0.463FP) [12].
2.4. [3H]Ketanserin binding to 5-HT2A receptors
The P2 pellets or the crude membrane preparations were resus-
pended in about 100 volumes of ice-cold 50 mM Tris^HCl bu¡er,
pH 7.4, and 1 ml aliquots of the suspension were incubated with
1 nM [3H]ketanserin (NEN, speci¢c. act. 80.9 Ci/mmol) with or with-
out di¡erent concentrations of the compounds to be tested, or vehicle
(ethanol), in triplicate. Non-speci¢c binding was determined using
1 WM methysergide.
After 15 min at 37‡C [13] the incubation was stopped by rapid
¢ltration under vacuum through GF/B ¢ber ¢lters, which were
washed with ice-cold bu¡er (3U4 ml), dried and counted in 4 ml of
Ultima Gold MV (Packard), in a liquid scintillation spectrometer with
about 65% counting e⁄ciency. Inhibition curves were ¢tted using the
equation of the sigmoidal dose-response curve (variable slope) built
into GraphPad Prism 2.0a for Power Macintosh (GraphPad Software,
San Diego, CA, USA). This analysis gave IC50 values (i.e. the drug
concentration inhibiting speci¢c binding by 50%) and the slope of the
curve, with their relative standard error.
3. Results
3.1. In vitro studies
Fig. 1A shows the in vitro e¡ects of di¡erent concentrations
of oleamide or oleic acid on the membrane £uidity of a crude
synaptosomal preparation (P2) from rat brain cortex. Concen-
tration-response curves were very similar for the two com-
pounds, which signi¢cantly lowered the FP value at 30 WM.
Oleamide at 10 WM, but not oleic acid, slightly but signi¢-
cantly reduced the FP value of the crude synaptosomal prep-
aration (Fig. 1A). This last ¢nding was not reproduced when
crude membrane preparations from rat brain cortex were used
(data not shown).
Table 1 shows the in vitro e¡ects of di¡erent concentra-
tions of oleamide and oleic acid on the binding properties
of 5-HT2A receptors in a crude synaptosomal preparation
(P2) from rat brain cortex. Up to 3000 nM, neither compound
a¡ected [3H]ketanserin binding to 5-HT2A receptors or the
IC50 (i.e. the a⁄nity) of K-methyl-5-HT, a 5-HT2A agonist.
Fig. 1. E¡ects of oleamide and oleic acid on the membrane £uidity
of rat brain cortical synaptosomes. A: For in vitro studies, the £uo-
rescence polarization (FP) value of synaptosomal membranes of
control rats was determined 30 s after the addition of the increasing
concentrations of oleamide or oleic acid or vehicle (1% ethanol, ¢-
nal concentration) into the cuvette. B: For ex vivo studies, rats
were treated intraperitoneally with di¡erent doses (12.5^100 mg/kg)
of oleamide or oleic acid. Controls received vehicle alone (ethanol:
water, 1:1, 2 ml/kg). Thirty minutes after treatment, rats were
killed, synaptosomal membranes prepared and the FP measured.
Each value is the mean þ S.E.M. of 6^9 measures from three di¡er-
ent experiments. The horizontal lines in (A) and (B) indicate the
mean FP, expressed as arbitrary units, of the brain synaptosomal
membranes of vehicle-treated rats. *: P6 0.05 di¡erent from vehicle
or vehicle-treated rats (Student’s t-test).
Table 1
In vitro and ex vivo e¡ects of oleamide and oleic acid on the bind-
ing properties of 5-HT2A receptors in the rat brain cortex
[3H]Ketanserin
speci¢c binding
(% of vehicle)
pIC50 of
K-methyl-5HT
(a 5HT2A agonist)
In vitro
Vehicle 100 5.96 þ 0.06
Oleamide (30 nM) 104 þ 2
Oleamide (300 nM) 110 þ 11 6.00 þ 0.03
Oleamide (3000 nM) 103 þ 3 5.82 þ 0.05
Oleic acid (30 nM) 109 þ 2
Oleic acid (300 nM) 107 þ 2 6.00 þ 0.04
Oleic acid (3000 nM) 104 þ 5 5.84 þ 0.09
Ex vivo
Vehicle 100 þ 3 5.35 þ 0.08
Oleamide (25 mg/kg) 98 þ 2 5.54 þ 0.05
Oleamide (50 mg/kg) 94 þ 3 5.45 þ 0.10
Oleic acid (100 mg/kg) 92 þ 4 5.38 þ 0.02
The binding of 1 nM [3H]ketanserin was measured on crude synap-
tosomal preparations from rat brain cortex. For the in vitro experi-
ments, the binding was measured in the presence of oleamide and
oleic acid or vehicle (1% ethanol, ¢nal concentration). Each value is
the mean þ S.E.M. of four replications. For the ex vivo experiments,
rats were injected intraperitoneally with oleamide and oleic acid, or
vehicle (ethanol:water, 1:1, 2 ml/kg). The brain cortex of two rats
per group were pooled and used for the binding experiments. Each
value is the mean þ S.E.M. of three replications. The inhibition
curve of K-methyl-5HT (four concentrations from 10 to 3000 nM)
was also plotted in the di¡erent conditions and the relative pIC50
were calculated (with their S.E.M.).
No signi¢cant di¡erences were found by Student’s t-test on these
parameters.
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3.2. Behavioral e¡ects
Rats treated with 25 and 100 mg/kg of oleamide, but not
with 100 mg/kg of oleic acid, showed very rapid loss of the
righting re£ex, more pronounced at the higher oleamide dose.
The loss of righting re£ex lasted for 90^150 min (data not
shown). Both oleamide and oleic acid suppressed locomotor
activity between 20 and 40 min after treatment, with very
similar e¡ects, the ED50 being respectively 16.4 mg/kg (95%
con¢dence limit: 15.4^30.8) and 21.8 mg/kg (95% con¢dence
limit: 11.3^23.6) (Fig. 2).
3.3. Ex vivo studies
As shown in Fig. 1B, synaptosomal membranes (P2) from
the brain cortices of rats treated with 100 mg/kg of oleamide
or oleic acid were slightly but signi¢cantly more £uid than
those of vehicle treated rats. The £uidizing e¡ect was not
apparent at lower doses (12.5 and 25 mg/kg) (Fig. 1B).
Table 1 shows that oleamide or oleic acid did not modify
the speci¢c binding of the 5-HT2A antagonist [3H]ketanserin
and the a⁄nity of the 5-HT2A agonist, measured ex vivo on a
P2 preparation from rat brain cortex.
4. Discussion
The present study indicates that oleamide, but not oleic
acid, induces loss of righting re£ex in rats, thus con¢rming
its sleep-inducing e¡ect [1,14]. However, our data do not show
that this hypnotic e¡ect is related to any alteration of brain
membrane homeoviscosity. The main ¢nding was that, at var-
iance with forecasts [8], both oleamide and oleic acid have
£uidizing e¡ects, with similar potency. In vitro studies showed
superimposable dose-e¡ect curves, high concentrations (v 10
WM) being required to signi¢cantly reduce membrane £uidity.
Ex vivo studies on brain membranes from rats treated with
oleamide or oleic acid showed a slight £uidizing e¡ect only
after 100 mg/kg of both compounds, and no such e¡ect at
lower doses. However, the loss of righting re£ex was observed
starting from 25 mg/kg of oleamide, whereas oleic acid was
ine¡ective even at 100 mg/kg, clearly indicating a lack of a
causal relationship between the £uidizing e¡ects of oleamide
and its sleep-inducing e¡ect. This relationship was previously
suggested only on the basis of the predicted e¡ects on mem-
brane homeoviscosity [8] ; however, this is the ¢rst study eval-
uating these properties of oleamide and oleic acid.
We also con¢rmed that oleamide suppresses locomotor be-
havior, with an ED50 very similar to those described [14,15].
This e¡ect was found using ethanol as vehicle, unlike Cheer et
al. [14], who found that oleamide was only active if dissolved
in oily solvent. Our ¢nding that oleic acid induced hypomo-
tility in rats with a potency similar to oleamide suggests that
the sleep-inducing and sedative e¡ects of oleamide might be
dissociated and mediated by di¡erent mechanisms.
The possibility that the decrease of membrane homeovis-
cosity, shared by oleamide and oleic acid, plays a role in the
sedative e¡ects of the two compounds appears unlikely be-
cause of the di¡erent doses required to produce the two e¡ects
(about 20 mg/kg for the sedative e¡ect and v100 mg/kg for
the £uidizing e¡ects). However, it cannot be excluded that an
in vivo e¡ect on membrane £uidity might be underestimated
ex vivo, i.e. after preparation of the synaptosomal mem-
branes.
Our results also exclude that an alteration of membrane
homeoviscosity underlies the potentiation of 5-HT2A-mediated
responses, previously described in vitro with much lower con-
centrations of oleamide (below 1 WM), but not oleic acid [3,4].
However, these e¡ects are controversial, since oleamide’s po-
tentiating action was not found on di¡erent cell lines [16] nor
in rat brain cortical slices [15]. Controversial results have been
also reported regarding a direct e¡ect of oleamide on 5-HT2A
receptors, since no e¡ect was found on [3H]ketanserin binding
[14] whereas 500 nM oleamide modestly, but signi¢cantly,
enhanced the a⁄nity of 5-HT for 5-HT2A receptors [15]. In
our studies, similar concentrations of oleamide did not di-
rectly interact with rat brain cortex 5-HT2A receptors, nor
did they increase the a⁄nity of a 5-HT2A agonist, either in
vitro or ex vivo. Thus, although endogenous oleamide levels
rise in the cerebrospinal £uid of sleep-deprived rats from 100
to about 500 nM [14], thus being compatible with the reported
potentiating e¡ects, the interaction of oleamide with 5-HT2
receptors has yet to be clari¢ed.
Mechanisms other than direct 5-HT2 receptor potentiation
are likely to be involved in some of the e¡ects. Cheer et al.
[15] reported that oleamide, from 2 to 10 mg/kg, modi¢ed 5-
HT2 receptor-mediated behavior in rats, in a manner that
appeared to involve the activation of cannabinoid CB1 recep-
tors (i.e. the oleamide e¡ects were mimicked by CB1 agonists
and antagonized by CB1 antagonists). Furthermore, rats
treated intraperitoneally with oleamide show the characteristic
‘tetrad’ of behaviors induced by cannabinoids [17]. CB1 re-
ceptors could be activated by oleamide itself with a⁄nity of 10
WM, as suggested by Basile et al. [15], or oleamide could
amplify the e¡ects of the endogenous CB1 ligand, anandamide
[17]. Oleamide is in fact a competitive substrate of fatty-acid
amide hydrolase (FAAH), the enzyme responsible for anand-
amide inactivation [18,19], and concentrations v 5 WM are
required to inhibit FAAH-mediated hydrolysis of anandamide
[17]. Our membrane homeoviscosity data indirectly imply that
these high concentrations of oleamide are likely to be reached
in the brain 30 min after sleep-inducing doses.
On the other hand, the e¡ects of oleamide on locomotor
activity are unlikely to be mediated by anandamide, as pre-
Fig. 2. E¡ects of oleamide and oleic acid on spontaneous locomotor
activity. Oleamide or oleic acid was injected intraperitoneally to rats
at the doses indicated, and motility was monitored in observation
cages with infrared beams, between 20 and 40 min after treatment.
Controls received vehicle alone (ethanol:water, 1:1, 2 ml/kg). Each
value, expressed as number of interruptions of the light beams, is
the mean þ S.E.M. of 4^8 rats. Locomotor activity was signi¢cantly
lower (P6 0.05) after doses v 25 mg/kg of both compounds than
after vehicle, according to Student’s t-test.
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viously suggested [17], for two reasons: (1) this e¡ect was not
[14] or very slightly [15] antagonized by CB1 antagonists and
(2) the e¡ect is shared by oleic acid (this study) which is not a
substrate of FAAH.
In conclusion, we report for the ¢rst time that oleamide and
oleic acid both increase membrane microviscosity in vitro and
ex vivo. These data clearly indicate a dissociation between the
£uidizing and the sleep-inducing e¡ects, the latter being seen
only with oleamide, but not oleic acid. The interaction of
oleamide with rat brain 5-HT2A receptors was ruled out as
well. Both compounds reduce locomotor activity, although
further studies are needed to demonstrate a causal relation-
ship with their £uidizing e¡ect. Our data also indicate that the
sedative and the sleep-inducing e¡ects of oleamide are medi-
ated by separate mechanisms.
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